VoyForums
[ Show ]
Support VoyForums
[ Shrink ]
VoyForums Announcement: Programming and providing support for this service has been a labor of love since 1997. We are one of the few services online who values our users' privacy, and have never sold your information. We have even fought hard to defend your privacy in legal cases; however, we've done it with almost no financial support -- paying out of pocket to continue providing the service. Due to the issues imposed on us by advertisers, we also stopped hosting most ads on the forums many years ago. We hope you appreciate our efforts.

Show your support by donating any amount. (Note: We are still technically a for-profit company, so your contribution is not tax-deductible.) PayPal Acct: Feedback:

Donate to VoyForums (PayPal):

Login ] [ Contact Forum Admin ] [ Main index ] [ Post a new message ] [ Search | Check update time | Archives: 1234 ]
Subject: Clinical Trial www.ovaturetrial.com


Author:
Jonathan
[ Next Thread | Previous Thread | Next Message | Previous Message ]
Date Posted: Thursday, September 06, 09:41:46am
Author Host/IP: 68.166.171.50

If this information isn't allow please remove it, but I thought some of the readers of this forums might find it useful.

I’m writing to inform ovarian cancer patients about a Phase III clinical trial for women with recurrent ovarian cancer called “OVATURE,” which stands for OVArian TUmor REsponse.

A new website, www.OVATUREtrial.com is designed to help ovarian cancer patients seeking information about the OVATURE trial. The website includes a page dedicated to answering patients’ questions, and a page to locate trial sites.

The trial seeks to recruit 235 women in the US and a total of 470 women globally. All patients on the trial will receive carboplatin weekly, in doses lower than that given when carboplatin is administered in the more typical once every three or four week dosing regimen. A change from receiving carboplatin (or cisplatin) every two to three weeks to a weekly carboplatin regimen has been reported to provide a tumor response in some patients with recurrent ovarian cancer.* In addition to learning more about the efficacy of phenoxodiol, researchers will learn more about the efficacy of weekly carboplatin.

If you have additional questions, you are welcome to email them to me at info@ovaturetrial.com and I will do the best I can to get the questions answered in a timely manner. Thank you.


* Piura B and Meirovitz M. Weekly single-agent carboplatin in heavily pretreated patients with recurrent ovarian, peritoneal and fallopian tube carcinoma. Eur J Gynaecol Oncol. 2005;26(4):386-90.

[ Next Thread | Previous Thread | Next Message | Previous Message ]


Post a message:
This forum requires an account to post.
[ Create Account ]
[ Login ]
[ Contact Forum Admin ]


Forum timezone: GMT-8
VF Version: 3.00b, ConfDB:
Before posting please read our privacy policy.
VoyForums(tm) is a Free Service from Voyager Info-Systems.
Copyright © 1998-2019 Voyager Info-Systems. All Rights Reserved.